2018 American Transplant Congress
Comparison of De Novo Rapamune versus Everolimus Maintenance Immunosuppression; an Interim Analysis
General Surgery, Ohio State University, Columbus, OH.
This is a 1 year interim analysis of the results of a 3 year, single center, randomized, prospective, open-label study comparing the efficacy and tolerability…2018 American Transplant Congress
Evaluation and Cost Burden of Inappropriately Drawn Immunosuppression Trough Levels in the Acute Care Setting at an Academic Medical Center
University of Virginia Health System, Charlottesville, VA.
Trough drug levels in narrow therapeutic index medications, such as CNI and mTOR inhibitors are used to estimate total drug exposure. Inappropriately measured trough levels…2018 American Transplant Congress
12-Months Evolution of Anti-HLA Antibodies Donor Specific Antibodies after Rescue Switch from CNi-Based Immunosuppressive Regimen to Belatacept in Kidney Allograft Recipients
IntroductionAfter kidney transplantation, long-term immunosuppression with calcineurin inhibitors (CNIs) or mTOR inhibitors (mTORi) leads to adverse effects, such as nephrotoxicity and proteinuria. Currently, available data…2018 American Transplant Congress
Effect and Reasons of Rescue Switch to Belatacept among 73 Calcineurin-Inhibitors Treated Kidney Allograft Recipients – A Three Years Retrospective Cohort, Single Center Study
IntroductionAfter kidney transplantation, long-term immunosuppression with calcineurin inhibitors (CNIs) or mTOR inhibitors (mTORi) leads to adverse effects, such as nephrotoxicity and proteinuria. Currently, available data…2018 American Transplant Congress
Incidence of Rejection and Antibody Formation after Immunosuppression Reduction in Patients with Biopsy Proven Polyomavirus Nephropathy
University of North Carolina, Chapel Hill, NC.
The purpose of this study is to determine the incidence of rejection and donor specific antibody (DSA) formation after immunosuppression reduction in patients with biopsy…2018 American Transplant Congress
Development of a Classification of Immunosuppressant Medication Nonadherence Tool to Enable the Objective Measurement of Immunosuppressant Medication Nonadherence in Kidney Transplant Patients
Imperial College Renal and Transplant Centre, London.
IntroductionKDIGO define nonadherence to immunosuppression as a 'deviation from the prescribed medication regimen sufficient to adversely influence the regimen's intended effect'. There is however, no…2018 American Transplant Congress
Polymorphisms of Nucleotide Factor of Activated T Cells Cytoplasmic 2 and 4 and the Risk of Acute Rejection Following Kidney Transplantation
Urology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Background: Acute rejection (AR) is a common complication of kidney transplantation. Nuclear factors of activated T cells (NFATs) are transcription factors involved in the activation…2018 American Transplant Congress
Immunophenotype of Cells Infiltrating the Graft Explains the Benefits of Belatacept
Previously, we found greater amounts of FoxP3 cells and lower amounts of CD4+/IL-17A+ and senescent cells in belatacept (Bela) patients compared to patients under cyclosporine…2018 American Transplant Congress
Burden of Infectious Complications after Upper Extremity Allotransplantation: A Matched Cohort Study
This study aimed to assess the infectious risk after upper extremity allotransplantation (UEA), a non-vital transplantation procedure requiring lifelong immunosuppression. A matched cohort study was…2018 American Transplant Congress
Efficacy and Safety of Bleselumab in Kidney Transplant Recipients: A Phase 2, Randomized, Open-Label Study
Introduction: Bleselumab (ASKP1240) is an anti-CD40 monoclonal antibody currently in development. This phase 2, randomized, open-label study assessed the efficacy and safety of bleselumab in…
- « Previous Page
- 1
- …
- 80
- 81
- 82
- 83
- 84
- …
- 138
- Next Page »